15 October 2021 | Friday | News
Xpert® Xpress CoV-2/Flu/RSV plus
Cepheid today announced that it has received CE Mark for Xpert Xpress CoV-2/Flu/RSV plus, a rapid molecular diagnostic test for qualitative detection of the viruses that cause COVID-19, flu A, flu B and respiratory syncytial virus (RSV) infections from a single patient sample. The new Plus version of the test provides a third gene target for the detection of SARS-CoV-2 to meet the challenge of future virus mutations. Xpert Xpress CoV-2/Flu/RSV plus is designed for use on one of Cepheid's more than 35,000 GeneXpert® systems worldwide and the results are available after about 36 minutes.
During the pandemic, several variants of the virus that causes COVID-19 have been documented worldwide. Viruses are constantly changing through mutation, and new variants of a virus are expected to emerge over time. The addition of a third gene target to the Plus version of Cepheid's CoV-2/Flu/RSV test provides broader coverage to mitigate the potential effects of future viral genetic drift.
"At this time of year, healthcare providers may face a number of viral infections whose symptoms overlap with COVID-19, including flu A, flu B, and respiratory syncytial virus. Rapid and accurate testing to detect current and future variants of COVID-19 and influenza viruses is becoming increasingly important," said Dr. David Persing,MD, Ph.D., Chief Medical and Technology Officer at Cepheid. "By being able to take a single sample and perform a single, highly sensitive multiplex test that detects and differentiates all four viruses, actionable results can be provided to better make decisions at the forefront of our healthcare systems."
Delivery of Xpert Xpress CoV-2/Flu/RSV plus to countries that accept CE marked products is expected to begin later this month.